Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
Information source: GlaxoSmithKline
Information obtained from ClinicalTrials.gov on October 04, 2010
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pulmonary Disease, Chronic Obstructive
Intervention: tiotropium bromide inhalation powder HandiHaler (Drug); fluticasone propionate/salmeterol inhalation powder DISKUS 250/50 (Drug)
Phase: Phase 4
Status: Not yet recruiting
Sponsored by: GlaxoSmithKline
Official(s) and/or principal investigator(s):
GSK Clinical Trials, Study Director, Affiliation: GlaxoSmithKline
US GSK Clinical Trials Call Center, Phone: 877-379-3718
The objective of this study is to demonstrate that, when added to tiotropium (TIO),
fluticasone propionate/salmeterol combination (FSC) DISKUS 250/50 significantly increases
exercise endurance time (EET) in the endurance shuttle walk test (ESWT), compared to TIO
alone. Male and female subjects at least 40 years of age with a diagnosis of Chronic
Obstructive Pulmonary Disease (COPD) are eligible. Subjects will be screened and consented
at or during a 6-week (wk) period prior to visit (V)1. The 4-wk run-in period begins
immediately after V1, when subjects receive open-label TIO plus as-needed relief inhaler
(identical formulations called albuterol in the US and salbutamol in Canada). At V2,
subjects will perform an incremental shuttle walk test (ISWT) to establish their maximal
walk response. The first ESWT will occur at V3. Subjects must demonstrate an EET of ≤20
min that is reproducible (EET from V3 and V4 varying by ≤2 min). Eligible subjects are then
randomized at V5 to either FSC 250/50mcg DISKUS twice daily plus open label TIO 18 mcg
daily, or placebo DISKUS twice daily plus open label TIO 18 mcg daily for the 4-wk treatment
period. The last study visit is V6. The primary efficacy measure is the difference between
the EET at V6 (wk-8) vs. V4 (wk-3; the last ESWT done before randomized study drug is
given). Secondary efficacy measures include V6 vs. V4 comparisons in exercise dyspnea scale
(EDS), exercise inspiratory capacity (EIC) and cardio-respiratory measurements (CRM), and V6
vs. V5 comparisons in dyspnea related to activities of daily living (baseline dyspnea index
and transition dyspnea index interviewer-administered [BDI-TDI]) and quality of life
(Chronic Respiratory Disease Questionnaire Self-administered Standardized [CRQ-SAS]). The
safety measure will be an assessment of adverse events. We will also attempt to validate
prospectively the minimal clinically-important difference (MCID) for a change in the EET
through correlation with dyspnea and quality of life results.
Official title: A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 Mcg Twice Daily Plus Tiotropium 18 Mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 Mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Primary outcome: Exercise Endurance Time
Exercise dyspnea scale
Exercise Inspiratory Capacity
Resting Inspiratory Capacity
baseline dyspnea index and transition dyspnea index interviewer-administered
Chronic Respiratory Disease Questionnaire Self-administered Standardized
We postulate that adding fluticasone propionate/salmeterol combination DISKUS 250/50 (FSC)
to tiotropium (TIO) will improve exercise endurance time (EET) and its clinical and
physiologic correlates, based on the combination of the three different mechanisms of action
represented. We propose to test this hypothesis by comparing outcomes of exercise testing
(Endurance Shuttle Walk Test; ESWT) with FSC added to TIO compared to those on TIO alone.
The primary objective is to demonstrate that, when added to TIO, FSC significantly increases
EET compared to TIO alone at Visit 6 (V6; week [wk]-8) vs. V4 (wk-3; the last ESWT before
Secondary efficacy measures will be as follows. Exercise dyspnea scale (EDS), exercise
inspiratory capacity (EIC) and cardio-respiratory measurements (CRM) will involve V6 vs. V4
comparisons. Dyspnea related to activities of daily living (ADLs) will be assessed using
the baseline dyspnea index and transition dyspnea index interviewer-administered (BDI-TDI),
and quality of life will be assessed using the Chronic Respiratory Disease Questionnaire
Self-Administered Standardized (CRQ-SAS). The BDI-TDI and CRQ-SAS will be based on
comparisons of data from V6 vs. V5. We will also attempt to validate prospectively the
minimal clinically-important difference (MCID) for a change in the EET through correlation
with dyspnea (Likert scale).
Safety evaluations will include the type, incidence and severity of adverse events.
This is a randomized, parallel-group study totalling 6 visits. Screening is at or up to 6
wk prior to V1, and includes a discussion of study procedures, a review of
inclusion/exclusion criteria, collection of informed written consent, adjustment of
medications and determination of spirometry pre- and post-albuterol/salbutamol. At V1,
subjects meeting inclusion criteria will be enrolled, familiarized with the incremental
shuttle walk test (ISWT), and given paper diaries.
The run-in will begin with the dispensing of open-label medications at the end of V1.
During the 4-wk run-in, subjects will have 3 visits (V2-V4). Open-label TIO will be taken
daily beginning after V1, and open-label relief inhaler (identical formulations called
albuterol in the US and salbutamol in Canada) will be taken on an as-needed basis beginning
after V1. Open-label medications will be withheld before V2, V3 and V4 (last dose of TIO,
the morning of the day before the visit; last dose of albuterol/salbutamol, at least 6 hr
before the start of the visit). At V2, subjects will be given open-label TIO, will undergo
ISWT 2. 5-hr post-TIO, and will be familiarized with the ESWT. At V3 and V4, subjects will
be given open-label TIO, and will undergo ESWT 2. 5-hr post-TIO. ESWT will be performed
again at V4 only if the EET at V3 was ≤20 min. Subjects will be studied at V5 if the EET
result from V4 is also ≤20 min and the EET from V3 and V4 vary from each other by ≤2 min;
otherwise, subjects will be withdrawn. The ESWT from V4 will be used as the baseline EET
for exercise-related outcomes because it will be the last ESWT done before double-blind
study drug is given.
Open-label medications will be withheld before V5 and V6 (last dose of TIO the morning of
the day before the visit; last dose of albuterol/salbutamol, at least 6 hr before the start
of the visit). At V5, subjects will undergo spirometry, lung volumes and diffusing
capacity, and will be randomized. Subjects will then be given open-label TIO and
double-blind DISKUS study drug, and undergo spirometry and lung volumes 2 hr
post-TIO/double-blind DISKUS study drug, and ESWT 2. 5 hr post-dose. Per randomization,
subjects will receive for 4 wk after V5, open-label TIO plus either FSC or placebo DISKUS.
Double-blind DISKUS study drug will be withheld before V6 (last dose the evening of the day
before the visit). V6 will be the last study visit, consisting of spirometry and lung
volumes, followed by open-label TIO and double-blind DISKUS study drug, spirometry and lung
volumes 2 hr post-dose, and the final ESWT 2. 5 hr post-dose.
All study visits will begin with a check-up to determine eligibility for further study
procedures. Details of the paper diary report will be reviewed after drug administration,
V2 through V6. Immediately after review of the paper diary, BDI (at V5), TDI (at V6) and
CRQ-SAS (V5 and V6) will be undertaken, and the post-dose study activities, as outlined
above, will follow.
Final contact will be by telephone approximately 2 wk after V6 or Early Withdrawal. The
total duration of the study will be 8 wk, including the 4 wk run-in and the 4 wk period of
double-blind plus open-label treatment. There will also be a screening period of up to 6 wk
prior to V1, and the 2-wk period after the final study visit for phone call follow-up.
Subjects at a subset of sites will undergo EIC and CRM during each ESWT using portable
telemetric monitoring (Oxycon Mobile; CareFusion, San Diego, CA).
Minimum age: 40 Years.
Maximum age: N/A.
Subjects eligible for enrolment in the study must meet all of the following criteria at
- Consent: A signed and dated written informed consent must be obtained from the
subject and/or subject's legally acceptable representative prior to study
- Age: at least 40 yr of age
- Sex: Male or Female
Females are eligible to participate only if they are currently not pregnant and not
lactating. In addition, female subjects should not be enrolled if they plan to become
pregnant during the time of study participation. A female is otherwise eligible to enter
and participate in the study if she is of:
- non-child bearing potential (i. e., physiologically incapable of becoming pregnant,
including any female who is post-menopausal); or,
- child-bearing potential, has a negative pregnancy test (urine) at screening, and is
committed to the consistent and correct use of an acceptable method of birth control,
starting at V2, throughout the clinical trial, and for a period after the trial to
account for elimination of the drug (minimum of six days), as defined by at least one
of the following:
- use of implants of levonorgestrel or etonogestrel
- percutaneous contraceptive patches
- use of injectable progestogen
- use of oral contraceptive (either combined estrogen/progestin or progestin only)
- use of any intrauterine device (IUD) with published data showing that the highest
expected failure rate is less than 1% per yr
- male partner is sterile (vasectomy with documentation of azoospermia; note that a
verbal report of azoospermia is acceptable) and is the sole sexual partner for that
female subject prior to the female subject's entry into the study
- double-barrier method; condom or occlusive cap (diaphragm or cervical/vault caps)
- abstinence: if not sexually active, must commit to complete abstinence from
Female subjects, with the exception of those who are post-menopausal or surgically
sterile, will undergo urine pregnancy tests approximately 7 days prior to first dose and
- Diagnosis: An established clinical history of COPD in accordance with the definition
of the American Thoracic Society (ATS).
- Severity of Disease: FEV1 post-albuterol/salbutamol at least 30 to no more than 80%
of predicted normal and FEV1/FVC ratio post-albuterol/salbutamol of no more than 0. 70
based on NHANES III reference values. Note that identical formulations of
short-acting beta-agonist are called albuterol in the US and salbutamol in Canada.
- Smoking History: A history of smoking at least 10 pack-yr is required. Pack-yr are
defined as the number of packs of cigarettes smoked per day multiplied by the number
of yr smoked. Please note that both current and previous smokers are eligible for
this study. Previous smoking is defined as no smoking for at least 6 months prior to
consent; subjects are otherwise considered "current" smokers.
- CXR: Chest radiograph, within 1 yr prior to consent, without findings suspected to
represent an active, clinically-significant process other than those believed to be
related to uncomplicated COPD.
- Use of TIO: A history of using TIO with compliance at least 80% starting at least 14
days prior to V1, and ending 24 hr prior to V1, is required. Please note that any
subject whose medical history precludes the safe use of TIO (such as significant
narrow-angle glaucoma, known urinary retention, etc) should not be started on TIO for
the purpose of this study.
Subjects meeting any of the following criteria at V1 must not be enrolled in the study:
- Asthma: A current diagnosis of asthma.
- Other Diseases/Abnormalities: Any significant disease that, in the opinion of the
investigator, would put the safety of the subject at risk through study
participation, or which would affect the efficacy analysis if the disease/condition
exacerbated during the study. Previously diagnosed cancer is considered a
significant disease unless it is in complete remission for 2 yr (no evidence of tumor
burden) at V1. Localized carcinomas of the skin that have been resected for cure are
- Other Respiratory Disorders: Subject had lung resection surgery (e. g., lung volume
reduction surgery or lobectomy) within 1 yr of V1 or has a significant respiratory
disorder other than COPD (e. g., lung cancer, sarcoidosis, active tuberculosis,
bronchiectasis, pulmonary fibrosis, sleep apnea, cystic fibrosis, or
alpha-1-antitrypsin deficiency) that, in the opinion of the investigator, would put
the safety of the subject at risk through study participation, or which would affect
the efficacy analysis if the disease/condition exacerbated during the study.
- Acute Exacerbation of COPD: active disease within the past 6 wk. For the purpose of
this study, an acute exacerbation of COPD will be identified using the following
criteria [Anthonisen, 1987; Burge, 2003; Anzueto, 2009]: either
- worsening of two or more of the following "major" symptoms for at least two
- sputum volume
- sputum purulence or
- worsening of any one major symptom together with any one of the following "minor"
symptoms for at least two consecutive days:
- sore throat
- nasal discharge or nasal congestion
- fever without other cause
- increased cough or wheeze.
- Pulmonary Rehabilitation: Participation in the early, active phase of a Pulmonary
Rehabilitation Program. For the purpose of this study, the "early, active" phase of
pulmonary rehabilitation consists of sessions, scheduled on a regular and frequent
basis (generally more than bi-weekly and for a total duration of at least 4 wk), held
at an institution or at home, that include exercise training among interventions such
as education and psychosocial support. Not included as the "early, active" phase of
pulmonary rehabilitation are reinforcement or maintenance sessions that follow an
"early, active" phase with interactions that are less frequent and less intense but
may be scheduled for a longer total duration such as 6 months to 1 yr.
- 12-Lead ECG: Potential subjects are excluded if they have a functioning cardiac
pacemaker. Otherwise, the investigator will determine the clinical significance of
any ECG abnormality, and whether it precludes the potential subject from entering the
- Drug Allergy: Any adverse reaction including immediate or delayed hypersensitivity to
any beta2-agonist, sympathomimetic drug, corticosteroid (intranasal, inhaled, or
systemic including any components of the formulations [e. g. lactose or milk
protein]), or atropine or its derivatives, including ipratropium or tiotropium.
- Body Mass Index (BMI): A BMI of 40 kg/m2 or higher.
- Use of ritonavir, ketoconazole or other potent inhibitors of CYP3A4: If any of these
medications are used prior to V1, they must be stopped at V1 if indicated.
- Other Exclusionary medications: If any of the following medications are used prior to
V1, they must be stopped as specified below.
(Medication, Washout period prior to V1) Any Investigational Drug, 30 days Oral or
parenteral corticosteroids, 30 days ICS, 30 days ICS/LABA combination products (e. g.,
ADVAIR, Symbicort), 30 days Theophylline, 7 days Tiotropium, 24 hr LABA (e. g. formoterol
or salmeterol), 12 hr Short-acting beta-agonists (e. g., albuterol or salbutamol), 6 hr
Ipratropium or ipratropium-containing combination products (e. g., Combivent), 6 hr Oral
beta-agonists, 6 hr
- Long-Term Oxygen Therapy (LTOT): Subject is on LTOT and is receiving supplemental
oxygen more frequently than nocturnal-only.
- Affiliation with investigator site: Subject is a study Investigator,
sub-Investigator, study coordinator, or employee of a participating Investigator or
immediate family member of the aforementioned.
Locations and Contacts
US GSK Clinical Trials Call Center, Phone: 877-379-3718
GSK Investigational Site, St. Charles, Missouri 63301, United States
GSK Investigational Site, Albany, New York 12205, United States
GSK Investigational Site, Montreal, Quebec H4J 1C5, Canada
GSK Investigational Site, Greenville, South Carolina 29615, United States
GSK Investigational Site, Spartanburg, South Carolina 29303, United States
GSK Investigational Site, The Woodlands, Texas 77380, United States
GSK Investigational Site, Richmond, Virginia 23229, United States
Starting date: July 2010
Last updated: July 15, 2010